HeartBeam Restructures Leadership to Streamline Costs and Accelerate 3D ECG Commercialization
BEAT•HeartBeam reorganized leadership under Founder Branislav Vajdic and Executive Chairman Rich Ferrari to streamline decision-making and cut costs, with former CEO Robert Eno moving to a consultant role. The company aims to commercialize its FDA-cleared 3D ECG and 12-lead synthesis platforms for arrhythmia and heart attack detection via global partnerships.
1. Strategic Reorganization
HeartBeam implemented a new corporate structure to enhance global commercialization, improve capital efficiency and reduce operating costs. The reorganization emphasizes agile implementation, streamlined decision-making and increased accountability across all business functions.
2. Leadership Assignments
Founder and President Branislav Vajdic and Executive Chairman Rich Ferrari will lead dedicated implementation teams focused on executing strategic initiatives and managing expenses. Former Chief Executive Officer Robert Eno will transition into a consulting role to advise on critical projects during the restructuring.
3. Commercialization Goals
The company plans to expand its market reach by leveraging its patented 3D ECG platform and synthesized 12-lead ECG technology across diverse healthcare channels. Targeted collaborations include partnerships with governments, health systems, ECG device manufacturers and wearable technology companies to drive product adoption.
4. Technology Development
HeartBeam’s 3D ECG system received FDA clearance for arrhythmia assessment in December 2024, followed by 12-lead synthesis software clearance in December 2025. Ongoing research focuses on heart attack detection capabilities, supported by more than 20 issued patents for its portable cardiac monitoring platform.
